Truvian raises $105 million to commercialize its automated blood-testing platform

27 Feb, 2021

Truvian raises $105 million to commercialize its automated blood-testing platform
Photo by Andre Hunter on Unsplash

– San Diego, California-based Truvian, a startup developing blood-testing technology that leans heavily on automation, today announced the close of an over $105 million oversubscribed series C round led by TYH Ventures, 7wireVentures’ Glen Tullman, and Wittington Ventures.
– Truvian says the funds will advance development of its benchtop blood testing system and enable the company to grow its product development team.
– More than 13 billion tests are performed in over 250,000 labs in the U.S. each year, and errors related to lab testing are more common than you might think. A 2014 study estimated that diagnostic errors for U.S. outpatients occur about 12 million times per year.

Biotechnology Health Care Health Diagnostics Life Science Medical Device North America
Crunchbase icon

Content report

The following text will be sent to our editors: